Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials

Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials

Science

First published in Journal of Diabetes Science and Technology on 2022 Jul.
J Diabetes Sci Technol. 2022 Jul 11:19322968221105864. doi: 10.1177/19322968221105864. Online ahead of print.

Authors: Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O.

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

(Bersacapavir) In Participants With Moderate Hepatic Impairment.